FDA Approves Orserdu (elacestrant) for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers. ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat. Orserdu is the first endocrine... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 30, 2023 Category: Drugs & Pharmacology Source Type: news

FDA Greenlights First Drug for ESR1-Mutated Breast Cancer
(MedPage Today) -- The FDA approved the selective estrogen receptor (ER) degrader elacestrant (Orserdu) for the treatment of postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - January 30, 2023 Category: American Health Source Type: news

Novel HER2 Assay to Predict HER2+ Breast Cancer Tx Response Novel HER2 Assay to Predict HER2+ Breast Cancer Tx Response
An award-winning genomic assay for measuring HER2 mRNA expression could help predict treatment responses in advanced HER2+ breast cancer and ultimately guide clinical decision-making, suggests study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 25, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Immune-Related Biomarkers Can Help Guide HER2+ Breast Cancer Tx Immune-Related Biomarkers Can Help Guide HER2+ Breast Cancer Tx
Immune-related gene expression signatures can predict pathologic complete response and could be used to help decide which HER2 therapies to use for which patients, say researchers.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 24, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Tucatinib Plus Trastuzumab Approved for HER2+ CRC Tucatinib Plus Trastuzumab Approved for HER2+ CRC
The combination of HER2-targeted agents is already approved for use in breast cancer and is now is the first treatment approved for HER2-positive colorectal cancer.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 20, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA OKs First Targeted Treatment for HER2-Positive Colorectal Cancer
(MedPage Today) -- The FDA has granted accelerated approval to tucatinib (Tukysa) in combination with trastuzumab (Herceptin) for adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer who have progressed... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 19, 2023 Category: Gastroenterology Source Type: news

FDA grants accelerated approval to tucatinib with trastuzumab for colorectal cancer
On January 19, 2023, the Food and Drug Administration (FDA) granted accelerated approval to tucatinib (Tukysa, Seagen Inc.) in combination with trastuzumab for RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following fluoropyrimidine-, oxaliplatin-, and (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 19, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Seagen Announces FDA Accelerated Approval of Tukysa (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer
BOTHELL, Wash.--(BUSINESS WIRE) January 19, 2023 -- Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tukysa (tucatinib) in combination with trastuzumab for adult patients... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 19, 2023 Category: Drugs & Pharmacology Source Type: news

Sacituzumab Govitecan in HR+/HER2- Metastatic Breast Cancer Sacituzumab Govitecan in HR+/HER2- Metastatic Breast Cancer
Is this drug therapy an effective therapeutic option for HR+/HER2- advanced breast cancer? What benefits might this treatment offer over single-agent chemotherapy?Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 11, 2023 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

An Impactful Experience With a Patient With Metastatic Breast Cancer An Impactful Experience With a Patient With Metastatic Breast Cancer
Kevin M. Kalinsky, MD, considers the impact of an antibody-drug conjugate in a patient with HER2-low breast cancer.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 6, 2023 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news

HER2 Low Breast Cancer: New Clinical Entity or Testing Artifact? HER2 Low Breast Cancer: New Clinical Entity or Testing Artifact?
One of the problems with the new subgroup of HER2 low tumors is that using current assays to measure low levels"is like weighing mice on a scale built for elephants," says one expert.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 5, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

A Big Year at the San Antonio Breast Cancer Symposium 2022 A Big Year at the San Antonio Breast Cancer Symposium 2022
Kathy Miller, MD, reflects on the impact of the positive data presented at SABCS for her patients with hormone receptor-positive, HER2-negative breast cancer.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 4, 2023 Category: Consumer Health News Tags: None MDAngle Source Type: news

Advocate for Yourself at the Doctor
Five ways to advocate for yourself and become responsibly selfish when you have HER2-postiive breast cancer (Source: WebMD Health)
Source: WebMD Health - January 4, 2023 Category: Consumer Health News Source Type: news

PIK3CA Mutation Predicts Worse Outcomes in HER2+ Breast Cancer PIK3CA Mutation Predicts Worse Outcomes in HER2+ Breast Cancer
The analysis suggests that PIK3CA mutation is associated with worse pathologic complete response and other outcomes. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 3, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Top Studies in Metastatic Breast Cancer From SABCS 2022 Top Studies in Metastatic Breast Cancer From SABCS 2022
Top studies in metastatic breast cancer from SABCS 2022 focus on practice-changing therapies for HR+/HER2- breast cancer, a follow-up of the monarchE trial, and results of the POSITIVE trial.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 29, 2022 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news